- Abstract:
-
INTRODUCTION
Expand abstract
Only a minority of esophageal cancers demonstrates a pathological tumor response (pTR) to neoadjuvant chemotherapy (NAC). 18F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) is often used for restaging after NAC and to assess response. Increasingly, it is used during therapy to identify unresponsive tumors and predict pTR , using avidity of the primary tumor alone. However, definitions of such metabolic tumor response (mTR) vary. We aimed t... - Publication status:
- Published
- Peer review status:
- Peer reviewed
- Version:
- Accepted manuscript
- Publisher:
- Society of Nuclear Medicine Publisher's website
- Journal:
- Journal of Nuclear Medicine Journal website
- Publication date:
- 2016-09-05
- Acceptance date:
- 2016-07-13
- DOI:
- EISSN:
-
2159-662X
- ISSN:
-
0161-5505
- URN:
-
uuid:75c0b8ec-7564-41be-a588-092e96e89593
- Source identifiers:
-
634139
- Local pid:
- pubs:634139
- Copyright holder:
- Society of Nuclear Medicine and Molecular Imaging
- Copyright date:
- 2016
- Notes:
- © 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Journal article
Predicting pathological response of esophageal cancer to neoadjuvant chemotherapy: the implications of metabolic nodal response for personalised therapy
Actions
Authors
Funding
Bibliographic Details
Item Description
Terms of use
Metrics
Altmetrics
Dimensions
If you are the owner of this record, you can report an update to it here: Report update to this record